PL376535A1 - Sole kwasu boronowego i ich zastosowanie w leczeniu zakrzepicy - Google Patents

Sole kwasu boronowego i ich zastosowanie w leczeniu zakrzepicy

Info

Publication number
PL376535A1
PL376535A1 PL376535A PL37653503A PL376535A1 PL 376535 A1 PL376535 A1 PL 376535A1 PL 376535 A PL376535 A PL 376535A PL 37653503 A PL37653503 A PL 37653503A PL 376535 A1 PL376535 A1 PL 376535A1
Authority
PL
Poland
Prior art keywords
thrombosis
treatment
boronic acid
ant
acid salts
Prior art date
Application number
PL376535A
Other languages
English (en)
Inventor
David Jonathan Madge
Mark Dolman
Sophie Marie Combe-Marzelle
John Joseph Deadman
Anthony James Kennedy
Sanjay Kumar Kakkar
Original Assignee
Trigen Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220764A external-priority patent/GB0220764D0/en
Priority claimed from GB0220822A external-priority patent/GB0220822D0/en
Priority claimed from GB0307817A external-priority patent/GB0307817D0/en
Priority claimed from GB0311237A external-priority patent/GB0311237D0/en
Priority claimed from GB0315691A external-priority patent/GB0315691D0/en
Application filed by Trigen Limited filed Critical Trigen Limited
Publication of PL376535A1 publication Critical patent/PL376535A1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL376535A 2002-09-09 2003-09-09 Sole kwasu boronowego i ich zastosowanie w leczeniu zakrzepicy PL376535A1 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0220764A GB0220764D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0220822A GB0220822D0 (en) 2002-09-09 2002-09-09 Boropeptides
GB0307817A GB0307817D0 (en) 2003-04-04 2003-04-04 Boronic acid compounds
GB0311237A GB0311237D0 (en) 2003-05-16 2003-05-16 Boronic acid compounds
GB0315691A GB0315691D0 (en) 2003-07-04 2003-07-04 Boropeptides
US48578603P 2003-07-08 2003-07-08

Publications (1)

Publication Number Publication Date
PL376535A1 true PL376535A1 (pl) 2006-01-09

Family

ID=31721886

Family Applications (2)

Application Number Title Priority Date Filing Date
PL03376439A PL376439A1 (pl) 2002-09-09 2003-09-09 Sole wielowartościowych metali z kwasami boronowymi
PL376535A PL376535A1 (pl) 2002-09-09 2003-09-09 Sole kwasu boronowego i ich zastosowanie w leczeniu zakrzepicy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL03376439A PL376439A1 (pl) 2002-09-09 2003-09-09 Sole wielowartościowych metali z kwasami boronowymi

Country Status (20)

Country Link
EP (8) EP1396269A1 (pl)
JP (3) JP2006509034A (pl)
KR (2) KR20050057295A (pl)
CN (2) CN100553639C (pl)
AT (3) ATE325611T1 (pl)
AU (3) AU2003263328A1 (pl)
BR (1) BR0314450A (pl)
CA (3) CA2535792A1 (pl)
CY (1) CY1105381T1 (pl)
DE (3) DE60317039T2 (pl)
DK (2) DK1400245T3 (pl)
ES (2) ES2263924T3 (pl)
HK (1) HK1063154A1 (pl)
IL (1) IL167294A (pl)
MX (2) MXPA05002661A (pl)
NZ (2) NZ539333A (pl)
PL (2) PL376439A1 (pl)
PT (1) PT1396270E (pl)
SI (2) SI1400245T1 (pl)
WO (3) WO2004022072A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405267D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
GB0405280D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
WO2006059082A1 (en) * 2004-11-30 2006-06-08 Trigen Limited Oxidised lipids as reversal agents for boronic acid drugs
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0515003D0 (en) * 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
BRPI0815713A2 (pt) * 2007-08-21 2015-02-10 Alza Corp Formulações lipossômicas de compostos de ácido borônico.
EA201070296A1 (ru) * 2007-08-21 2010-08-30 Алза Корпорейшн Липосомные композиции для введения in vivo соединений бороновой кислоты
US8389232B2 (en) * 2008-05-13 2013-03-05 The Regents Of The University Of California Fluorescence detection of poison oak oil
KR101690571B1 (ko) 2008-06-17 2016-12-28 밀레니엄 파머슈티컬스 인코퍼레이티드 보로네이트 에스테르 화합물 및 이의 제약학적 조성물
EP2355824A4 (en) * 2008-11-21 2012-11-07 Iroko Cardio Llc METHOD FOR REDUCING THROMBOCYTOPENIA AND THROMBOZYTOPENIC IMPORTANT MORTALITY
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
JP6662865B2 (ja) * 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ボロン酸誘導体
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN114685453A (zh) 2016-06-21 2022-07-01 奥瑞恩眼科有限责任公司 杂环脯氨酰胺衍生物
CN109187155B (zh) * 2018-07-27 2021-08-13 临沂大学 一种水样中有效硼的提取纯化方法和一种硼同位素组成的测试方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN113121666B (zh) * 2021-03-10 2023-09-12 厦门大学 抗菌肽Scybaumancin105-127及其应用
CN114106346B (zh) * 2021-10-29 2023-04-18 重庆第二师范学院 一种稀土双金属电致化学发光材料及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5856695A (ja) 1981-09-28 1983-04-04 Nitto Boseki Co Ltd 新規なトロンビン測定用基質
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5574014A (en) 1988-04-28 1996-11-12 Thrombosis Research Institute Inhibitors of trypsin-like enzymes
IL90244A (en) 1988-05-11 1993-05-13 Du Pont Merck Pharma Peptide-drug compositions, for buccal and nasal administration, containing :-aminoboronic acid derivatives
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
US5288707A (en) 1990-08-13 1994-02-22 Sandoz Ltd. Borolysine peptidomimetics
US5648338A (en) 1990-11-06 1997-07-15 Thrombosis Research Institute Inhibitors and substrates of thrombin
GB9024129D0 (en) 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
CA2109526C (en) 1991-04-30 1998-01-20 Dwight M. Peterson Liquid detergents with an aryl boroic acid
GB9224702D0 (en) 1992-11-25 1993-01-13 Thrombosis Res Inst Boronic ester synthesis
FR2701951B1 (fr) * 1993-02-24 1995-06-09 Adir Nouveaux derives peptidiques de l'acide boronique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CA2153656A1 (en) 1993-03-03 1994-09-15 Nigel Scott Cook Peptide boronic acid derivatives having protease inhibiting activity
WO1994021650A1 (en) * 1993-03-24 1994-09-29 The Du Pont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5563127A (en) 1993-03-24 1996-10-08 The Dupont Merck Pharmaceutical Company Boronic acid and ester inhibitors of thrombin
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
IL109319A0 (en) 1993-04-27 1994-07-31 Du Pont Merck Pharma Amidino and guanidino substituted boronic acid compounds
US5658885A (en) 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
SE9900043D0 (sv) 1999-01-11 1999-01-11 Astra Ab New use
US5681978A (en) * 1993-07-07 1997-10-28 Washington State University Research Foundation Method for the stereocontrolled synthesis of stegobinone and useful borane intermediates
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
IL111175A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
EP0722449A1 (en) * 1993-10-07 1996-07-24 The Du Pont Merck Pharmaceutical Company Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
US5431842A (en) 1993-11-05 1995-07-11 The Procter & Gamble Company Liquid detergents with ortho-substituted phenylboronic acids for inhibition of proteolytic enzyme
GB9401483D0 (en) 1994-01-26 1994-03-23 Sandoz Ltd Organic compounds
FR2721611B1 (fr) 1994-06-22 1996-09-27 Adir Nouveaux dérivés peptidiques de l'acide boronique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent .
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
GB9502985D0 (en) 1995-02-16 1995-04-05 Thrombosis Res Inst Enzyme inhibitors
GB9515489D0 (en) 1995-07-28 1995-09-27 Sandoz Ltd Organic compounds
GB9613718D0 (en) * 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
GB9724786D0 (en) * 1997-11-25 1998-01-21 Danbiosyst Uk Oral delivery system
AU5920400A (en) 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
SE9904483D0 (sv) 1999-12-08 1999-12-08 Astra Ab New use
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
CA2435146C (en) * 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
DE10133786A1 (de) 2001-07-16 2003-02-06 Boehringer Ingelheim Pharma Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis

Also Published As

Publication number Publication date
ES2263924T3 (es) 2006-12-16
DE60305113D1 (de) 2006-06-14
DK1400245T3 (da) 2006-08-28
DE60317039T2 (de) 2008-07-31
EP1695712A3 (en) 2008-01-09
EP1466916A1 (en) 2004-10-13
SI1400245T1 (sl) 2006-10-31
EP1396270B1 (en) 2006-05-10
CN100553639C (zh) 2009-10-28
AU2003263343A1 (en) 2004-03-29
EP1695711A3 (en) 2008-01-02
IL167294A (en) 2008-11-03
EP1561466A2 (en) 2005-08-10
DE60304956D1 (de) 2006-06-08
CA2535788A1 (en) 2004-03-18
DK1396270T3 (da) 2006-08-28
WO2004022071A1 (en) 2004-03-18
EP1466917A1 (en) 2004-10-13
WO2004022070A1 (en) 2004-03-18
CN100447151C (zh) 2008-12-31
ES2264515T3 (es) 2007-01-01
EP1466916B1 (en) 2007-10-24
CN1681517A (zh) 2005-10-12
NZ539334A (en) 2007-11-30
KR20050057294A (ko) 2005-06-16
BR0314450A (pt) 2005-07-26
CA2535792A1 (en) 2004-03-18
EP1400245B1 (en) 2006-05-03
CA2536010A1 (en) 2004-03-18
ATE324899T1 (de) 2006-06-15
AU2003263328A1 (en) 2004-03-29
WO2004022072A1 (en) 2004-03-18
EP1400245A1 (en) 2004-03-24
AU2003263333A1 (en) 2004-03-29
CY1105381T1 (el) 2010-07-28
MXPA05002662A (es) 2005-09-20
PL376439A1 (pl) 2005-12-27
EP1561466A3 (en) 2006-08-23
JP2006503903A (ja) 2006-02-02
DE60305113T2 (de) 2006-12-07
NZ539333A (en) 2007-02-23
SI1396270T1 (sl) 2006-10-31
EP1396270A1 (en) 2004-03-10
DE60317039D1 (de) 2007-12-06
EP1695711A2 (en) 2006-08-30
MXPA05002661A (es) 2005-08-19
DE60304956T2 (de) 2007-01-25
ATE376551T1 (de) 2007-11-15
EP1695712A2 (en) 2006-08-30
CN1684693A (zh) 2005-10-19
JP2006511593A (ja) 2006-04-06
JP2006509034A (ja) 2006-03-16
PT1396270E (pt) 2006-08-31
ATE325611T1 (de) 2006-06-15
EP1396269A1 (en) 2004-03-10
KR20050057295A (ko) 2005-06-16
HK1063154A1 (en) 2004-12-17

Similar Documents

Publication Publication Date Title
PL376535A1 (pl) Sole kwasu boronowego i ich zastosowanie w leczeniu zakrzepicy
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
DK1326613T3 (da) Anvendelse af substituerede imidazo[1,2-a] pyridin-, -pyrimidin- og -pyrazin-3-yl-amin-derivater til fremstilling af lægemidler til NOS-inhibering
ATE248837T1 (de) Chinuclidin-acrylamide
MY127126A (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
CA2003190A1 (en) Pharmaceutical compositions containing n-(3,4-dimethoxycinnamoyl) anthranilic acid
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
WO2002000166A3 (en) New compounds useful as antibacterial agents
SE0102057D0 (sv) New Salts I
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
WO2000066550A8 (en) New compounds
SE0102058D0 (sv) New Salts II
WO2002098843A3 (en) Certain salts of discodermolide acid, pharmaceutical compositions containing them and their use in treating tumors
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
CA2301590A1 (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
HK1050203A1 (en) Novel fusidic acid derivatives.
AU7441100A (en) Therapeutic agents
ATE441653T1 (de) Phosphorenthaltende verbindugnen mit antithrombitische wirkung
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
WO1993018059A3 (en) L-thiazolidine-4-carboxylic acid derivative, processes for the preparation thereof and the use thereof in therapy
PL369845A1 (pl) Zastosowanie pochodnych kwasu 4-oksobutanowego w leczeniu stanów zapalnych
WO2000074678A8 (fr) Analgesique
TH25306A (th) วิธีของการใช้สำหรับยับยั้งการสูญเสียกระดูกและการลดคอเลสเทอรอลในซีรัม

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)